Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $862.00 Price Target at Leerink Partners

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective reduced by Leerink Partners from $980.00 to $862.00 in a report issued on Tuesday. Leerink Partners currently has a market perform rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also commented on REGN. Truist Financial lowered their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Morgan Stanley dropped their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Royal Bank of Canada reduced their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Sanford C. Bernstein dropped their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Finally, Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $983.65.

Regeneron Pharmaceuticals Stock Up 4.5 %

Regeneron Pharmaceuticals stock opened at $697.05 on Tuesday. The firm has a market capitalization of $76.60 billion, a price-to-earnings ratio of 17.25, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. The firm’s fifty day moving average price is $719.16 and its two-hundred day moving average price is $918.90. Regeneron Pharmaceuticals has a 1-year low of $642.00 and a 1-year high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $11.86 EPS. On average, equities research analysts predict that Regeneron Pharmaceuticals will post 37.75 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of REGN. Centaurus Financial Inc. purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $118,000. Czech National Bank grew its position in Regeneron Pharmaceuticals by 7.0% during the third quarter. Czech National Bank now owns 21,617 shares of the biopharmaceutical company’s stock worth $22,725,000 after buying an additional 1,405 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Regeneron Pharmaceuticals by 32.6% in the 3rd quarter. GAMMA Investing LLC now owns 1,436 shares of the biopharmaceutical company’s stock valued at $1,510,000 after acquiring an additional 353 shares in the last quarter. Miracle Mile Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 12.6% during the 3rd quarter. Miracle Mile Advisors LLC now owns 2,562 shares of the biopharmaceutical company’s stock valued at $2,693,000 after acquiring an additional 286 shares during the last quarter. Finally, Greenfield Savings Bank grew its holdings in shares of Regeneron Pharmaceuticals by 28.6% during the third quarter. Greenfield Savings Bank now owns 612 shares of the biopharmaceutical company’s stock worth $643,000 after purchasing an additional 136 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.